

e-ISSN:2582-7219



INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH

IN SCIENCE, ENGINEERING AND TECHNOLOGY

Volume 7, Issue 9, September 2024



6381 907 438

INTERNATIONAL STANDARD SERIAL NUMBER INDIA

 \bigcirc

Impact Factor: 7.521

 \bigcirc

6381 907 438 🔛 ijmrset@gmail.com



Avoiding Immune Rejection in Transplanted Stem Cell Therapies

Simrith Reddy Pulicharla

Oakdale High School, Frederick, Maryland, USA

ABSTRACT:

Background:

Regenerative medicine combined with genetically engineered and modified **stem cells**, has the ability to revolutionize how we treat a wide range of diseases. These advanced therapies offer hope and have the potential to repair damaged tissues, restore lost functions and even cure chronic conditions that have very few effective treatments currently, from neurodegenerative disorders like Parkinson's and Alzheimer's to heart disease, diabetes, and spinal cord injuries, stem cell-based treatments are at the cutting edge of medical research. However, despite their huge potential, one of the biggest challenges in this field is the immune system's tendency to reject transplanted stem cells, treating them as foreign threats instead of solutions.

The human immune system plays an essential role in protecting the body from infections, diseases, pathogens, etc. At the heart of this defense mechanism is its ability to differentiate between what belongs in the body and what doesn't—a process largely governed by **Major Histocompatibility Complex (MHC)** molecules. These protein markers, present on the surface of nearly every cell, serve as identification tags that allow the immune system to recognize its own native cells. The immune system constantly scans for these markers, and when it does encounter cells with unfamiliar MHC molecules - such as those from a stem cell transplant - it perceives them as foreign and mounts an immune response. This response primarily involves **T-cells**, a type of white blood cell, which identify and attack non-matching cells in an attempt to eliminate the potential threat. This immune response can lead to inflammation, reduced effectiveness of the treatment, and in many cases, the complete destruction of the transplanted cells. There are many factors that contribute to how strong a rejection could be, the genetic differences between the donor & the patient, the type of stem cells used and whether or not the patient's immune system has been previously exposed to similar antigens.

This mechanism, while essential when protecting the body on a regular basis, becomes a major obstacle in stem cell therapies. Given the critical role MHC molecules play in immune rejection, researchers have explored various strategies to mitigate and lessen this response. Immunosuppressive drugs, for example, work by suppressing the immune system's activity to prevent it from attacking transplanted cells. However, while these drugs can be effective, they come with significant drawbacks, including an increased risk of infections, higher susceptibility to certain cancers, and organ toxicity. Other strategies, such as inducing immune tolerance through mixed chimerism—where a recipient's immune system is partially reprogrammed to accept foreign cells—or utilizing regulatory T-cells to suppress immune responses, have shown promise but they remain complex and difficult to implement reliably & consistently.

The challenge of immune rejection highlights the need for new & innovative solutions that can both enhance integration of transplanted stem cells while minimizing risks. Developing a safer and more reliable method to overcome immune rejection is essential in unlocking the full potential of stem cell based regenerative medicine.

I. MECHANISMS OF IMMUNE REJECTION

The rejection of transplanted stem cells is primarily driven by the immune system's ability to distinguish between self & non-self. This process is run primarily by Major Histocompatibility Complex (MHC) molecules, which serve as unique cellular identifiers. While these markers are essential in protecting the body from pathogens, they transform into a major hurdle for regenerative medicine. When a patient receives transplanted stem cells that carry MHC molecules differing from their own, the immune system could perceive them as foreign invaders, initiating a series of defensive responses with the goal of eliminating the 'threat'.



This immune rejection process unfolds in several stages, each involving different components of the immune system:

- 1. Antigen Recognition & Activation The first step in immune rejection occurs when antigen-presenting cells (APCs), such as dendritic cells, process and display MHC molecules from transplanted stem cells to T-Cells in the lymph nodes. If these foreign MHC molecules do not match the patient's, they activate cytotoxic T-cells (CD8+ T-cells) and helper T-cells (CD4+ T-cells), setting off an immune response.
- T-cell causes Cytotoxicity Once activated, cytotoxic T-cells directly attack the transplanted stem cells by releasing perfins and granzymes, proteins that create pores in the target cell membranes and trigger apoptosis (programmed cell death). Meanwhile, helper T-cells amplify this response secreting pro-inflammatory cytokines, escaping the immune activity even more.
- 3. Innate Immune System Involvement While T-Cells have a controlling role in this process, Natural Killer (NK) cells and Macrophages also play huge roles in this process. NK cells are particularly problematic because they target stem cells that have low or absent MHC expression, a common characteristic of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). Macrophages, on the other hand, release inflammatory mediators and engulf damaged stem cells, this worsens tissue inflammation.
- 4. Chronic Rejection & Inflammation In cases where the immune response is not immediately fatal to the transplanted cells, chronic rejection can happen. This involves steady low-level immune attacks, this can then lead to fibrosis, reduced cell function & graft failure. Chronic rejection is a particularly challenging obstacle in long-term term cell therapies, as the immune system gradually adapts and becomes more efficient at identifying and killing transplanted cells.

In the end the Immune System is a complex, multi-step process that involves multiple components. To make stem-cell based therapies a realistic part of regenerative medicine, solutions need to be developed that understand and bypass these mechanisms.

II. CURRENT STRATEGIES TO PREVENT IMMUNE REJECTION & THEIR LIMITATIONS

Taking into account the immune system's natural tendency to reject transplanted cells, multiple approaches have already been developed & pioneered to improve the success of transplantation. While these strategies all have their merits, they all come with both pros & cons.

1. **Immunosuppressive Drugs** - One of the most common strategies is the use of immunosuppressive drugs, drugs that suppress the immune system and reduce the likelihood of rejection. Medications such as **cyclosporine**, **tacrolimus**, **and corticosteroids** suppress T-cell activation, preventing them from attacking transplanted cells.

However, while these drugs can improve short-term graft survival, they can come with some serious side effects. Longterm use can increase the risk of infections, kidney damage, high blood pressure, and even certain cancers due to a weakened immune system. THis is why these drugs are not a long term solution for many patients, as the risk of complications outweighs the benefits.

2. MHC Modification & Universal Stem Cells - To directly address the issue of immune recognition, researchers have explored genetically modifying stem cells to reduce or eliminate MHC molecule expression. By deleting certain immune recognition markers using technology like CRISPR-Cas9, researchers aim to create universal donor cells that can avoid immune detection.

While this method has shown potential, complete MHC deletion can make it extremely vulnerable to Natural Killer cells. This might happen because the immune system could classify them as abnormal as these stem cells would have no recognizable surface proteins.

3. Immune Tolerance Induction - Another strategy involves reprogramming the immune system to tolerate transplanted stem cells. One approach is mixed chimerism, where donor and recipient immune cells coexist through bone marrow transplantation, training the patient's immune system to recognize the new cells as part of



the body. **Regulatory T-cells (Tregs)**, a subset of immune cells that suppress immune responses could also be introduced to promote tolerance. Despite these advantages on paper, these techniques are complex & risky. Bone marrow transplants require **intensive conditioning**, which can damage the patient's existing immune system. Manipulating Tregs is also extremely difficult due to **dose control issues**, and potential risks of **immunosuppression imbalance**.

While current strategies are effective in many cases, they only provide partial solutions, none offer fully reliable, longterm solutions. While immunosuppressive drugs, genetic modifications, immune tolerance techniques each offer promising ways to reduce rejection, they all come with significant limitations. Immunosuppressants weaken the immune system, genetic modifications introduce potential risks and immune tolerance strategies are complex to implement, and biomaterial shielding can interfere with cell function.

Abstract Conclusion:

By addressing the immune rejection of transplanted stem cells, we pave the path to totally transforming the field of regenerative medicine. By exploring innovative solutions and refining current technologies, we can overcome current obstacles to hopefully take advantage of the full potential of stem cells and their benefits in the future.

Introduction:

The field of regenerative medicine has made huge strides in the past decades, primarily due to the development of stem cell therapies. These treatments hold the potential to repair damaged tissues and restore lost functions, offering hope to patients suffering from crippling diseases. However, a major obstacle prevents stem cells from achieving widespread use—immune rejection. This article aims to explore the challenge of immune rejection, evaluate current strategies & their limitations, and go through potential solutions to improve the success of stem cell transplantation.

Synthetic Cloaking Devices for Transplanted Stem Cells

Developing **synthetic cloaking devices** for transplanted stem cells could be a unique & innovative solution to combat immune rejection. These protective barriers would serve as **biocompatible shields**, preventing immune recognition and attack while still allowing the cells to function effectively. These cloaking devices, no matter the way they're implemented, whether it's nanoparticle based cloaking, hydrogel encapsulation or biomimetic coating, could significantly improve the success rate of stem cell therapies.

- 1. Nanoparticle-Based Cloaking This approach involves encapsulating stem cells with nanoparticles designed to obscure their immunogenic markers. Not to mention, these nanoparticles could be engineered to release immunosuppressive drugs locally, reducing the risk of immune rejection even further without the side effects of traditional immunosuppression. Not to mention, these nanoparticles could be made to mimic the surface properties of the patient's native cells, decreasing the likelihood of immune rejection even more.
- 2. Hydrogel Cocoon Hydrogels are water-based gels that can form a biocompatible & porous barrier around transplanted stem cells. They would allow for nutrient and gas exchange while blocking immune cell infiltration. Hydrogels could also be coupled with bioactive molecules, such as growth factors or anti-inflammatory agents, to support & help with cell survival.
- 3. **Biomimetic Coating** In this approach, transplanted stem cells could be coated with a thin layer of **biocompatible material** that mimics the patient's cellular environment. These coatings, made from either **natural or synthetic polymers** could help stem cells resemble the **extracellular matrix**, making them less detectable by the immune system.

These synthetic cloaking strategies take a more discreet and less direct approach to combating immune rejection. Rather than suppressing the entire immune system, these methods focus on hiding the transplanted stem cells or masking their foreign markers, allowing them to blend in with the patients' cells.

III. BIOMATERIAL SCAFFOLDS

Biomaterial scaffolds offer another promising solution to immune rejection, as they provide both protection and functional support for the transplanted cells. These scaffolds could serve as physical barriers that protect stem cells



from immune recognition & support their ability to integrate and function inside the patient.

- 1. Immune Protection These scaffolds could be designed to act as biocompatible barriers that prevent immune cells from recognizing that the transplanted cells are foreign. Using advanced materials like **semi-permeable membranes**, we could allow nutrients and waste matter to pass through while blocking off immune cells.
- 2. Immune Modulation These biomaterial scaffolds could also be coupled with immune-modulatory agents, which can suppress the immune system locally, reducing the chances of rejection even further. This solution combines both physical protection and targeted immune suppression.
- **3.** Biodegradable Scaffolds & Consistent Drug Delivery One of the most important & beneficial features of these scaffolds could be their biodegradability. Over time, the scaffold could be engineered to break down, leaving no excess foreign material in the body. On top of that, these scaffolds could also be engineered to release constant microdoses of immunosuppressive drugs if needed. This can help maintain a stable environment long enough for the stem cells to successfully incorporate itself into the patient.

These biomaterial scaffolds show a dual approach to dealing with immune rejection, by providing physical protection & immune modulation. This combination of shielding & support increases the chance of the stem cells integrating successfully.

Implantable Microenvironments that "Reprogram" the Immune Response

Implantable microenvironments that "reprogram" the immune response could offer a unique and innovative way to combat immune rejection. Instead of simply hiding or protecting the stem cells like we do in the other approaches, this approach would modify the immune landscape around them, making the body more tolerant while keeping the overall immune system unharmed. These microenvironments would act as controlled spaces, allowing for extremely precise control over the conditions inside them.

Controlled Antigen Exposure - These microenvironments could be engineered to introduce the patient's immune system to the transplanted stem cells in a gradual & controlled way. By releasing small, consistent doses of stem cell antigens over time, the body could slowly adapt and recognize them as non-threatening. This technique also very closely copies the natural immune mechanisms the body already has, decreasing the chance of potential failure & immune rejection.

Reprogramming Immune Cells (Locally) - Instead of blocking the immune cells, these microenvironments could work to reprogram them. By using biomaterials that release signals mimicking the body's natural immune regulation, these microenvironments could make immune cells take on a regulatory or anti-inflammatory role instead of launching an attack. This approach is another way to train the immune system to accept the transplanted cells instead of suppressing it altogether.

Microenvironment Adaptation - These implantable microenvironments could also be designed with adaptive biomaterials that respond to immune activity. For example, sensors inserted inside the microenvironment could detect early signs of inflammation or immune activation. After detecting these changes, the microenvironment could initiate an appropriate response, like releasing anti-inflammatory drugs or changing its structure to minimize interactions with immune cells. This would create an advanced, self-regulating system that's constantly on the lookout for immune responses or sudden changes.

By combining controlled antigen exposure, immune cell reprogramming & dynamic adaptation, implantable microenvironments provide an advanced & active approach to preventing immune rejection. Rather than shielding or hiding transplanted cells, this approach reshapes the immune response itself.

IV. CONCLUSION

The immune rejection of transplanted stem cells presents a major challenge in the field of regenerative medicine. Synthetic cloaking devices, biomaterial scaffolds, and implantable microenvironments offer promising solutions in



overcoming this obstacle. Each of these solutions addresses immune rejection in a different way, by hiding the transplanted cells, providing physical support, or reprogramming a small chunk of the immune system. These strategies, while hypothetical, are based on current research and provide a foundation and starting point for future research in stem cell therapies.

REFERENCES

- 1. Morizane, A., & Takahashi, J. (2019). Immune responses in cell therapy using induced pluripotent stem cells. *Stem Cell Reports*, 12(3), 393–398. https://doi.org/10.1016/j.stemcr.2019.01.010
- Zhao, T., Zhang, Z. N., Rong, Z., & Xu, Y. (2011). Immunogenicity of induced pluripotent stem cells. *Nature*, 474(7350), 212–215. https://doi.org/10.1038/nature10135
- Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, C., ... & Schrepfer, S. (2019). Hypoimmunogenic pluripotent stem cells evade immune recognition and resist allogeneic rejection. *Nature Biotechnology*, 37(3), 252– 258. https://doi.org/10.1038/s41587-019-0030-6
- Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013). Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. *Cell Stem Cell*, 12(4), 407–412. https://doi.org/10.1016/j.stem.2013.01.006
- 5. Dutta, D., Heo, I., & Clevers, H. (2017). Disease modeling in stem cell-derived 3D organoid systems. *Trends in Molecular Medicine*, 23(5), 393–410. https://doi.org/10.1016/j.molmed.2017.02.007
- 6. Yamanaka, S. (2007). Strategies and new developments in the generation of patient-specific pluripotent stem cells. *Cell Stem Cell*, 1(1), 39–49. https://doi.org/10.1016/j.stem.2007.05.013





INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH IN SCIENCE, ENGINEERING AND TECHNOLOGY

| Mobile No: +91-6381907438 | Whatsapp: +91-6381907438 | ijmrset@gmail.com |

www.ijmrset.com